Worldwide License for Mino-Lok™ is Now Complete CRANFORD, N.J., March 23, 2017, CTXR, /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius ) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™. South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center ( MDACC ), and
http://bit.ly/2o9Lrub
No comments:
Post a Comment